Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 21.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 002A27 | T. Kojima ; K. Funahashi ; N. Takahashi ; D. Kato ; H. Matsubara ; Y. Hattori ; Y. Yabe [Japon] ; N. Ishiguro | THU0124 Importance of monitoring of C-reactive protein level to predict achievement of better clinical outcome during treatment with tocilizumab in patients with rheumatoid arthritis |
| 002A43 | H. Yamanaka ; M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu [Japon] ; S. Takei ; T. Takeuchi [Japon] ; Y. Tanaka ; Y. Sano [Japon] ; T. Koike [Japon] | THU0092 The advantage of early intervention by tocilizumab for rheumatoid arthritis - full analysis of all-case postmarketing surveillance in 7,901 patients in japan |
| 002B40 | Y. Kanayama ; T. Kojima ; Y. Hirano [Japon] ; N. Takahashi ; K. Funahashi ; D. Kato ; H. Matsubara ; Y. Hattori ; Y. Oishi [Japon] ; N. Ishiguro | SAT0155 Radiographic progression of cervical lesions and hands in patients with rheumatoid arthritis receiving infliximab treatment from japanese tbc registry; two years of follow-up |
| 002B48 | Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. Ishiguro | SAT0143 Analysis of Patients Who Obtained Remission by Disease Activity Score After Tocilizumab Treatment But Still had Low Disease Activity by Clinical Disease Activity Index, and Examination of Points for Treatment Intensification |
| 002B52 | T. Kojima [Japon] ; N. Takahashi [Japon] ; K. Funahashi [Japon] ; D. Kato [Japon] ; Y. Hattori [Japon] ; M. Hanabayashi [Japon] ; N. Asai [Japon] ; N. Ishiguro [Japon] | SAT0139 Importance of Concomitant MTX Use During Treatment with Tocilizumab in Patients with Rheumatoid Arthritis |
| 002B57 | S. Hirabara [Japon] ; T. Kojima [Japon] ; N. Takahashi [Japon] ; M. Hanabayashi [Japon] ; K. Terabe [Japon] ; Y. Yoshioka [Japon] ; N. Ishiguro [Japon] | SAT0134 Clinical Efficacy of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Tocilizumab; Results from Japanese Multicenter Registry System TBCR |
| 002B65 | M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu ; T. Takeuchi [Japon] ; S. Takei ; Y. Tanaka ; H. Yamanaka ; Y. Sano [Japon] ; H. Yaguramaki [Japon] ; T. Koike [Japon] | SAT0120 Characteristics Associated with Better Effectiveness and Safety in Rheumatoid Arthritis Patients Treated with Intravenous Tocilizumab: Results from Full Analysis of All-Patient Postmarketing Surveillance in Japan |
| 002B67 | M. Hanabayashi [Japon] ; T. Kojima [Japon] ; N. Takahashi [Japon] ; K. Funahashi [Japon] ; D. Kato [Japon] ; Y. Hattori [Japon] ; N. Ishiguro [Japon] | SAT0118 The Clinical Outcome of Abatacept Treatment in Biologic NaÏVe Patients with Rheumatoid Arthritis in Multi-Center Clinical Practice |
| 002B86 | H. Ishikawa ; Y. Hirano ; A. Kaneko ; D. Kida ; T. Sato ; T. Kojima ; T. Kanamono [Japon] ; N. Ishiguro | SAT0093 Pregnancy in patients with rheumatoid arthritis treated witn biological agents: Results of the 8-year of japanese tbc registry |
| 002C12 | S. Asai [Japon] ; T. Kojima [Japon] ; N. Takahashi [Japon] ; K. Funahashi [Japon] ; D. Katoh [Japon] ; Y. Hattori [Japon] ; M. Hanabayashi [Japon] ; K. Terabe [Japon] ; N. Ishiguro [Japon] | SAT0013 Risk Factors for Progression of Large Joint Destruction in Patients with Rheumatoid Arthritis Based on Incident Rate of Joint Surgery During Treatment with Biologics |
| 002E67 | Y. Tanaka ; M. Harigai ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Yamamoto [Japon] ; M. Kanazawa ; Y. Murakami ; T. Yoshinari [Japon] ; D. Baker [États-Unis] ; N. Miyasaka ; T. Koike [Japon] | FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy |
| 003066 | Y. Hirano ; N. Takahashi ; A. Kaneko [Japon] ; D. Kida [Japon] ; Y. Oishi ; T. Kojima ; N. Ishiguro | AB0591 Analysis of rheumatoid arthritis patients who were treated with abatacept with rapid effectiveness from japanese multicenter registry system of biological therapy |
| 003067 | Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; T. Shioura ; N. Asai ; T. Kobayakawa ; K. Saito [Japon] ; N. Ishiguro | AB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry |
| 003092 | N. Asai ; T. Kobayakawa ; K. Saito ; T. Shioura ; Y. Yabe [Japon] ; T. Kojima ; A. Kaneko [Japon] ; N. Ishiguro | AB0564 Continuation and remission rates of tocilizumab treatment based on improvement in patient global assessment: 2-year study based on the tsurumai biologics communication registry |
| 003093 | N. Takahashi [Japon] ; T. Kojima [Japon] ; K. Funahashi [Japon] ; D. Kato [Japon] ; H. Matsubara [Japon] ; Y. Hattori [Japon] ; N. Ishiguro [Japon] | AB0563 Impact of the history and the type of previous biologic treatment on abatacept efficacy in rheumatoid arthritis patients |
| 003121 | H. Ishikawa [Japon] ; A. Kaneko ; D. Kida ; T. Sato ; T. Kojima [Japon] ; N. Ishiguro [Japon] | AB0534 Efficacy and safety to use halfdose abatacept therapy between 24weeks in patients with rheumatoid arthritis in japanese |
| 003143 | A. Kaneko ; N. Takahashi ; D. Kida ; Y. Hirano [Japon] ; H. Ishikawa ; T. Kojima ; N. Ishiguro | AB0515 Predictors of clinical remission (DAS28CRP<2.6) in patients with RA who were treated with abatacept |
| 003184 | Y. Hirano ; N. Takahashi ; A. Kaneko [Japon] ; D. Kida [Japon] ; Y. Oishi ; T. Kojima ; N. Ishiguro | AB0339 A retrospective study on rapidness of efficacy in abatacept terapy in patients with rheumatoid arthritis from japanese multicenter registry system |
| 003185 | Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. Ishiguro | AB0338 Evaluation of tocilizumab treatment continuation rate stratified by time of start of administration |
| 003187 | Y. Kanayama ; T. Kojima ; Y. Hirano ; Y. Yabe [Japon] ; N. Takahashi ; K. Funahashi ; Y. Oishi ; N. Ishiguro | AB0336 Radiographic progression of cervical lesions in patients with rheumatoid arthritis receiving tocilizumab treatment comparison with infliximab treatment from japanese tbcr |
| 003239 | Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon] | AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort |
| This area was generated with Dilib version V0.6.34. |  |